From riociguat to mosliciguat: Giessen lung research advances new therapeutic principle for pulmonary vascular disease

Дата публикации: 24-09-2026 15:38:00

Promising Phase 2 results from the international PHocus study point to the potential of the investigational inhaled drug mosliciguat for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In 135 patients at 87 centers in 20 countries, mosliciguat achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 and significantly improved exercise capacity. The results support further clinical development, with a global Phase 3 trial in approximately 375 patients already underway.
Joint press release of the Institute for Lung Health (ILH) and the German Center for Lung Research (DZL)

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Von Riociguat zu Mosliciguat: Gießener Lungenforschung entwickelt neues therapeutisches Prinzip für pulmonale Gefäße	0	14.52	24-09-2026
2	Once-daily inhaled mosliciguat yields improvements in PH-ILD	0	16.09	09-10-2026
3	Un tratamiento obtiene resultados prometedores en hipertensión pulmonar	0	10	09-04-2026
4	Rein Therapeutics RENEW Trial Enrollment Runs Ahead Of Schedule As R&D And G&A Spending Decline	0	7.06	15-08-2026
5	Mukoviszidose: Dreifachtherapie im frühen Kindesalter besonders wirksam	0	6.08	24-09-2026
6	Quarterly IL-6 antibody safely cuts inflammation in phase 2 study	0	12.63	16-09-2026
7	Winrevair safety in Group 2/3 PH similar to Group 1 PAH	0	12.83	16-10-2026
8	DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study	0	16.67	05-05-2026
9	STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study	0	5.33	10-08-2026
10	Data on PDE9 inhibition in HF mixed; more research planned	0	13.32	12-10-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.38. Источник: idw-online.de.